单磷酸阿糖腺苷和利巴韦林用于手足口病治疗临床比较

Comparison of Clinical Effects Between Vidarabine Monophosphate and Ribavirin in the Treatment of Hand-foot-mouth Disease

目的探讨单磷酸阿糖腺苷和利巴韦林治疗手足口病的临床疗效。方法选择182例手足口病患儿,随机分为观察组和对照组,各91例。观察组给予单磷酸阿糖腺苷治疗,对照组给予利巴韦林治疗。结果观察组总有效率为92.31%,对照组为81.32%,观察组有效率高于对照组(P<0.05)。观察组皮疹消退时间、退热时间、口腔炎愈合时间、住院时间均少于对照组,差异有统计学意义(P<0.05)。两组不良反应无明显差异(P>0.05)。结论单磷酸阿糖腺苷治疗手足口病较利巴韦林疗效好,且安全可靠,不良反应少。

Objective To discuss clinical effects of Vidarabine Monophosphate and Ribavirin in the treatment of HFMD.Methods 182 patients with handfoot-mouth diseases were selected into observation group and control group, 91 cases in each group. The observation group was treated with Vidarabine Monophosphate, the control group was treated with Ribavirin. Results The total effective rate in observation group（92.31%） was higher than control group（81.32%） significantly（P〈0.05）. The fever subsidence time, erythra regression time, the stomatitis healing time, the hospital time in observation group were lower than control group significantly（P〈0.05）.There were no difference in adverse reactions between two groups（P〈0.05）. Conclusion The clinical effect of Vidarabine Monophosphate is better than Ribavirin in the treatment of HFMD. It is safe and reliable, with few adverse reactions.